
Home » DEBIOPHARM AND AURIGENE ENTER INTO AGREEMENT TO IDENTIFY AND DEVELOP SELECTIVE COMPOUNDS FOR IMMUNO-ONCOLOGY TARGETS
DEBIOPHARM AND AURIGENE ENTER INTO AGREEMENT TO IDENTIFY AND DEVELOP SELECTIVE COMPOUNDS FOR IMMUNO-ONCOLOGY TARGETS
The Debiopharm Group (Debiopharm), a global independent biopharmaceutical development company specialising in oncology and serious medical conditions, and Aurigene Discovery Technologies Ltd (Aurigene), a Bangalore-based discovery services company, signed a research agreement to identify and develop compounds for two innovative immuno-oncology targets.
Pipeline
Review
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
08Feb
-
09Feb
-
15Feb
-
16Feb
-
22Feb
-
07Mar